The neurobiologic consequences of Down syndrome
- PMID: 2875770
- DOI: 10.1016/0361-9230(86)90074-2
The neurobiologic consequences of Down syndrome
Abstract
Trisomy of the whole or distal part of human chromosome 21 (HSA 21) (Ts21) results in Down Syndrome (DS), which is characterized in part by mental retardation and associated neurological abnormalities. Structural abnormalities observed frequently include reduced brain weight, decreased number and depth of sulci in the cerebral cortices, neuronal heterotopias, and reduced numbers of specific populations of neurons, such as granule cells, in the cerebral cortices. Abnormalities in the structure of cells, primarily of the dendrites, are observed in portions of the neuraxis, such as the hippocampus, cerebellum, and cerebral cortices. Functional abnormalities in membrane properties in peripheral structures and in neurotransmitter enzyme systems in both peripheral and central structures are observed also. Brains of DS individuals over the age of 40 exhibit the characteristic neuropathologic and neurochemical stigmata of Alzheimer's disease (AD). The cholinergic and noradrenergic systems appear to be particularly vulnerable. To elucidate the mechanisms responsible for these abnormalities, identification of the genes located in the distal part of HSA 21 and the systematic study of animal model systems with close genetic homology are essential.
Similar articles
-
Neurological phenotypes for Down syndrome across the life span.Prog Brain Res. 2012;197:101-21. doi: 10.1016/B978-0-444-54299-1.00006-6. Prog Brain Res. 2012. PMID: 22541290 Free PMC article. Review.
-
Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome.Neurosci Lett. 2002 May 24;324(3):209-12. doi: 10.1016/s0304-3940(02)00210-0. Neurosci Lett. 2002. PMID: 12009525
-
Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.Neurobiol Dis. 2017 Oct;106:76-88. doi: 10.1016/j.nbd.2017.06.010. Epub 2017 Jun 21. Neurobiol Dis. 2017. PMID: 28647555
-
Genetic linkage in the mouse of genes involved in Down syndrome and Alzheimer's disease in man.Brain Res. 1987 Sep;388(3):215-21. doi: 10.1016/0169-328x(87)90028-3. Brain Res. 1987. PMID: 2960420
-
Alterations of brain circuits in Down syndrome murine models.J Chem Neuroanat. 2011 Dec;42(4):317-26. doi: 10.1016/j.jchemneu.2011.09.002. Epub 2011 Sep 16. J Chem Neuroanat. 2011. PMID: 21946025 Review.
Cited by
-
N-butylidenephthalide attenuates Alzheimer's disease-like cytopathy in Down syndrome induced pluripotent stem cell-derived neurons.Sci Rep. 2015 Mar 4;5:8744. doi: 10.1038/srep08744. Sci Rep. 2015. PMID: 25735452 Free PMC article.
-
Neurological phenotypes for Down syndrome across the life span.Prog Brain Res. 2012;197:101-21. doi: 10.1016/B978-0-444-54299-1.00006-6. Prog Brain Res. 2012. PMID: 22541290 Free PMC article. Review.
-
Sex differences in the cholinergic basal forebrain in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.Brain Pathol. 2014 Jan;24(1):33-44. doi: 10.1111/bpa.12073. Epub 2013 Jul 19. Brain Pathol. 2014. PMID: 23802663 Free PMC article.
-
DSCAM/PAK1 pathway suppression reverses neurogenesis deficits in iPSC-derived cerebral organoids from patients with Down syndrome.J Clin Invest. 2021 Jun 15;131(12):e135763. doi: 10.1172/JCI135763. J Clin Invest. 2021. PMID: 33945512 Free PMC article.
-
Sensitive pupil response of early-onset alzheimer's patients to a dilute mixture of cholinergic antagonist and α-Adrenergic stimulant.Environ Health Prev Med. 1999 Apr;4(1):49-53. doi: 10.1007/BF02931250. Environ Health Prev Med. 1999. PMID: 21432171 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical